Monopar Therapeutics (MNPR) traded above its average 12-month analyst target of $120.23, last changing hands at $123.84/share. This suggests the stock has outperformed the existing analyst expectation, though the article is truncated and provides no details on new fundamentals, guidance, or analyst revisions.
Monopar Therapeutics (MNPR) traded above its average 12-month analyst target of $120.23, last changing hands at $123.84/share. This suggests the stock has outperformed the existing analyst expectation, though the article is truncated and provides no details on new fundamentals, guidance, or analyst revisions.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
